Nancy Lurker - 09 Feb 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
CEO, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2023
Net transactions value
$0
Form type
4
Filing time
13 Feb 2023, 15:56:53 UTC
Previous filing
10 Jan 2023
Next filing
15 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +17,533 +11% $0.000000 170,559 09 Feb 2023 Direct F1
transaction EYPT Common Stock Options Exercise $0 +20,000 +12% $0.000000 190,559 09 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -20,000 -33% $0.000000 40,000 09 Feb 2023 Common Stock 20,000 $0.000000 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -17,533 -50% $0.000000 17,534 09 Feb 2023 Common Stock 17,533 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,745 shares acquired on January 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 The restricted stock units vest in three annual installments beginning February 9, 2023.
F3 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.